fda glp-1 compounding warning october 2025 letters Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the FDA Adverse Event Reporting System FDA Targets Non-Approved GLP-1 Compounds,

For individuals using GLP-1 treatments long term, this formula serves as an ideal companion to help support ongoing gut health and digestive comfort

Receptor agonists: Substances, often synthetic, that bind to and activate cell receptors

Januvia is a brand of sitagliptin manufactured by Merck Sharp and Dohme

The most frequently prescribed options in the medical industry are semaglutide (the active compound found in Wegovy and Ozempic) and tirzepatide (the active compound in Zepbound and Mounjaro)

What would your advice be to patients who come for a second opinion regarding use of prescription GLP1 drugs

If youre anything like us, it can be easy to get so caught up in taking care of everyone else, that your own needs get lost in the ether